Curaleaf Holdings, Inc., a prominent provider of consumer cannabis products, has announced a significant transition in its stock structure. Starting June 5, 2026, the company will implement a 1-for-3 reverse stock split of its subordinate voting shares. This move follows consultations with major U.S. stock exchanges and is aimed at positioning Curaleaf for a potential uplisting in response to recent developments in cannabis regulation.
The Board of Directors sanctioned this reverse stock split, which will decrease the number of outstanding subordinate voting shares while increasing the per-share trading price. This adjustment is intended to align with the share price criteria set forth by U.S. exchanges and may foster an environment conducive to uplisting. Additionally, the reverse split aims to enhance trading conditions by ensuring the shares remain above thresholds established by certain retail brokerage firms, thus broadening institutional investment participation.
Chairman and CEO Boris Jordan emphasized the strategic importance of this decision, framing it as a step toward achieving a listing on a major U.S. stock exchange. He pointed to the rescheduling of medical cannabis as a promising avenue for uplisting, and highlighted the anticipated regulatory clarity from upcoming hearings. Jordan expressed confidence that these developments will facilitate improved access to capital and a diverse investor base, further legitimizing the cannabis industry in public markets.
Upon completion of the reverse stock split, Curaleaf expects to see the number of outstanding subordinate voting shares reduced from approximately 698.7 million to around 232.9 million shares. The stock will continue trading on the Toronto Stock Exchange under the symbol “CURA.” A detailed letter of transmittal will be sent to registered shareholders, outlining the process for exchanging their pre-split shares for post-split securities.
The company further indicated that the reverse stock split will not create fractional shares, as any fractions will be rounded to the nearest whole share. This consolidation will also proportionately adjust the share prices and numbers for outstanding stock options and convertible securities.
Curaleaf is recognized for its comprehensive involvement in the cannabis industry, from cultivation to distribution, and operates multiple brands that serve both medical and adult-use markets. The company’s robust international footprint includes operations across Europe, Canada, and Australasia, backed by pioneering science and innovative production techniques.
As Curaleaf gears up for this significant milestone, establishing a strong presence in U.S. markets remains a focal point. The company encourages stakeholders to stay informed through its investor resources as it seeks to navigate the evolving landscape of cannabis regulation and market dynamics.
